Table 6. Cox proportional hazard regression model for disease-free survival.
| Univariate | Multivariate | |||
| crude HR (95% CI) | P-value | adjusted HR (95% CI) | P-value | |
| Group | ||||
| Basiliximab | 0.98 (0.65–1.47) | 0.913 | 0.53 (0.27–1.06) | 0.073 |
| Steroid | 1.00 (reference) | – | 1.00 (reference) | – |
| Gender | ||||
| Female | 1.00 (reference) | – | 1.00 (reference) | – |
| Male | 1.05 (0.58–1.89) | 0.83 (0.46–1.51) | 0.541 | |
| Age (y) | ||||
| <50 | 1.00 (reference) | – | 1.00 (reference) | – |
| ≥50 | 0.76 (0.51–1.13) | 0.72 (0.48–1.09) | 0.118 | |
| AFP1 | ||||
| <200 | 1.00 (reference) | – | ||
| ≥200 | 1.64 (1.08–2.49) | |||
| Transplant year | ||||
| 2003–2005 | 0.98 (0.65–1.47) | 0.57 (0.29–1.11) | 0.098 | |
| 2006–2009 | 1.00 (reference) | – | 1.00 (reference) | – |
| Child–Pugh score2 | ||||
| 5–6 | 1.00 (reference) | – | ||
| 7–9 | 0.65 (0.42–1.01) | |||
| 10–15 | 0.90 (0.47–1.73) | |||
| Diabetes mellitus | ||||
| No | 1.00 (reference) | – | ||
| Yes | 1.33 (0.67–2.64) | |||
| HBV | ||||
| No | 1.00 (reference) | – | ||
| Yes | 0.50 (0.27–0.92) | 0.025 | ||
| Cirrhosis | ||||
| No | 1.00 (reference) | – | ||
| Yes | 0.47 (0.26–0.85) | 0.012 | ||
| HCC | ||||
| Primary liver cancer | 1.00 (reference) | – | ||
| Recurrent hepatocellular carcinoma | 1.07 (0.52–2.22) | 0.855 | ||
| No. of tumor | ||||
| <2 | 1.00 (reference) | – | ||
| ≥2 | 1.30 (0.87–1.95) | 0.201 | ||
| Diameter of largest tumor (cm) | ||||
| <5 | 1.00 (reference) | – | ||
| ≥5 | 2.57 (1.71–3.86) | <0.0001 | ||
| TNM tumor staging for HCC, n (%) | ||||
| Stage I | 1.00 (reference) | – | 1.00 (reference) | – |
| Stage II | 1.72 (0.87–3.40) | 0.118 | 1.56 (0.77–3.15) | 0.219 |
| Stage III+ | 5.47 (2.90–10.29) | <0.0001 | 3.02 (1.35–6.78) | 0.007 |
| Milan Criteria2, n (%) | ||||
| Within Milan | 0.22 (0.13–0.38) | <0.0001 | ||
| Beyond Milan | 1.00 (reference) | – | ||
| UCSF Criteria1, n (%) | ||||
| Within UCSF | 0.22 (0.13–0.36) | <0.0001 | 0.37 (0.20–0.71) | 0.003 |
| Beyond UCSF | 1.00 (reference) | – | 1.00 (reference) | – |
| Preoperative antiviral therapy, n (%) | ||||
| No | 1.00 (reference) | – | ||
| Yes | 1.36 (0.88–2.10) | 0.172 | ||
1
n = 173;
2
n = 177.
†
In the multivariate model, data of 173 subjects were included.
AFP = alpha-fetoprotein; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; UCSF, University of California San Francisco.